ERBB2 and breast cancer: Based on this observation, a phase I/II clinical trial for secondary prevention of BrM in HER2+ BC has been developed, enrolling patients after an initial local therapy to receive T‐DM1 with or without temozolomide, with the goal to prevent and decrease incidence of new BrM.119